Date updated:04-27-2009
No description available

-
NVAX
Novavax - $3.28
- -13.00%
- $3.44
Novavax (NVAX): NVAX can produce a vaccine from an emergent strain of flu virus in 12 weeks according to the CEO. Currently in Phase II trials, the FDA could give then emergency authorization power

-
BCRX
Biocryst Pharmace - $9.55
- -8.17%
- $9.57
BioCryst Pharmaceuticals (BCRX): BCRX is currently in Phase I testing (thus highly unlikely to get authorization power from the FDA) for drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.

-
AVII
Avi Biopharma - $1.46
- -5.81%
- $1.54
AVI Biopharma (AVII): AVII is in the process with a joint venture with the Department of Defense’s Transformational Medical Technologies Initiative, with the goal of developing drugs for cardiovascular diseases.

-
DVAX
Dynavax Technolog - $1.26
- -2.33%
- $1.27
Dynavax Technologies (DVAX): DVAX is currently in Phase II testing of its universal flu vaccine, the company also has several other drugs in its pipeline, and joint ventures with GlaxoSmithKline (GSK), Astra Zeneca, and Novartis. DVAX has $1.7 in cash per share, and no debt.

-
SVA
Sinovac Biotech - $7.55
- -3.82%
- $7.70
Sinovac Biotech (SVA): SVA is a Chinese based biotech company that engages in the sale of vaccines that protect against human infectious in mainland China. The company’s principal drug ‘Anflu’ provides a split virus influenza vaccine.

-
ADLS
Adls - $0.00
- N/A
- $N/A
Advanced Life Sciences Holdings (ADLS): ADLS’s leading drug called ‘Cethromycin’ is a once-a-day treatment for pneumonia. Currently under review by the FDA, ADLS has tested Cethromycin in Phase III testing.

-
QDEL
Quidel Corporatio - $13.23
- -0.30%
- $13.34
Quidel Corp (QDEL): QDEL makes the QuickVue test which is used during flu season. Recently the company reported a wider then expected loss because of a mild flue season, which led to weak demand for their flu test kit.

-
GNBT
Generex Biotechno - $0.50
- -1.96%
- $0.508
Generex Biotechnology (GNBT): GNBT operates several different sprays for weight-loss, and type I and type II diabetes. GNBT is also working on Phase I and Phase II testing for SARS, and Influenza.
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Navellier & Associ...
- 3. Calamos Advisors
- 4. Argus Management
- 5. Bernard L. Madoff Inve...
- show all
- Top Do-It-Yourself Portfolios
- » Joseph Russell Portfolio 1
- » Albo's First Portfolio
- » Darrell Werth Portfolio 1
- » Echo5Joker's Portfolio
- » jgroov Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
Not a Stockpickr member? Join the community today -- for free.Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about...
By Roberto Pedone Posted on Nov. 20, 2009 According to Jim Cramer, options expiration is driving the current market selloff. He pointed out that the only stocks that we...
By Roberto Pedone Posted on Nov. 19, 2009 According to CNBC’s “Fast Money” traders, the stock market is showing no signs of stopping its current bull run. Joe Ter...
By Jonas Elmerraji Posted on Nov. 18, 2009 There are plenty of reasons for stocks to have the attention of short-sellers. Waning financials, a deteriorating business mo...
A. The only one I own : SLX,
too hard pick a winner out all of them
These are some of the stocks mentioned on TheStreet.com TV recently. Click the URL below each stock to watch the videos. more
These are the stocks from Jim Cramer's Nov. 1 Lightning Round. We list the stocks on which he is BULLISH and BEARISH.... more
Analyst Upgrades or Estimate Increases for Nov. 20, 2009. Read more here. more













04/28/2009 19:03 PM CDT Asked by interslice
will there be any significant movers tomorrow?